Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by Second Line Capital LLC

Second Line Capital LLC grew its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 29.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,511 shares of the biotechnology company's stock after buying an additional 11,393 shares during the quarter. Second Line Capital LLC's holdings in Viking Therapeutics were worth $1,992,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of VKTX. S.A. Mason LLC grew its stake in Viking Therapeutics by 20.0% during the 4th quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 300 shares in the last quarter. Blue Trust Inc. grew its stake in Viking Therapeutics by 75.9% during the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 309 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its stake in Viking Therapeutics by 7.4% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,980 shares of the biotechnology company's stock worth $221,000 after purchasing an additional 345 shares in the last quarter. Arizona State Retirement System grew its stake in Viking Therapeutics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 28,929 shares of the biotechnology company's stock worth $1,164,000 after purchasing an additional 353 shares in the last quarter. Finally, Activest Wealth Management grew its stake in Viking Therapeutics by 24.1% during the 4th quarter. Activest Wealth Management now owns 2,165 shares of the biotechnology company's stock worth $87,000 after purchasing an additional 420 shares in the last quarter. 76.03% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Viking Therapeutics

In other Viking Therapeutics news, Director Sarah Kathryn Rouan acquired 1,240 shares of the firm's stock in a transaction dated Monday, March 31st. The shares were acquired at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the acquisition, the director now directly owns 1,240 shares of the company's stock, valued at $29,946. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.10% of the stock is owned by insiders.

Viking Therapeutics Stock Up 1.4%

VKTX traded up $0.37 on Thursday, hitting $27.62. 989,912 shares of the company traded hands, compared to its average volume of 4,288,942. The company has a 50 day moving average of $26.02 and a 200-day moving average of $35.68. The stock has a market capitalization of $3.10 billion, a PE ratio of -27.64 and a beta of 0.75. Viking Therapeutics, Inc. has a 12-month low of $18.92 and a 12-month high of $81.73.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). The company's quarterly revenue was up .0% on a year-over-year basis. During the same period last year, the business posted ($0.26) earnings per share. On average, research analysts anticipate that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Viking Therapeutics in a report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price target for the company. Scotiabank assumed coverage on Viking Therapeutics in a report on Thursday, February 13th. They set a "sector outperform" rating and a $102.00 price target for the company. Citigroup assumed coverage on Viking Therapeutics in a report on Friday, February 7th. They set a "neutral" rating and a $38.00 price target for the company. Truist Financial reaffirmed a "buy" rating and set a $75.00 price target (down from $95.00) on shares of Viking Therapeutics in a report on Monday, April 28th. Finally, HC Wainwright reissued a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $87.15.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.